HUMA (Humacyte) EBIT : $-144.37 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Humacyte EBIT?

Humacyte's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-36.76 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-144.37 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Humacyte's annualized ROC % for the quarter that ended in Sep. 2024 was -161.29%. Humacyte's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -360.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Humacyte's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -26.50%.

Humacyte EBIT Historical Data

The historical data trend for Humacyte's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte EBIT Chart

Humacyte Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-64.32

-22.13

-5.77

-104.18

Humacyte Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial												-24.53	-23.38	-30.08	-54.15	-36.76

Competitive Comparison of Humacyte's EBIT

For the Biotechnology subindustry, Humacyte's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Humacyte's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Humacyte's EV-to-EBIT falls into.

Humacyte EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-144.37 Mil.

Humacyte (NAS:HUMA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Humacyte's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-120.932 * ( 1 - 0% )	/	( (48.97	+	100.988)	/ 2 )
=	-120.932	/	74.979
=	-161.29 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	138.281	-	10.958	-	( 93.563	-	max(0, 17.757	-	96.11	+	93.563	))
=	48.97

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	114.764	-	11.713	-	( 20.571	-	max(0, 20.942	-	23.005	+	20.571	))
=	100.988

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Humacyte's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-147.056	/	( ( (41.356 + max(-12.408, 0))	+	(40.263 + max(-15.62, 0)) )	/	2 )
=	-147.056	/	( ( 41.356	+	40.263 )	/	2 )
=	-147.056	/	40.8095
=	-360.35 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.547)	-	(10.958	+	0	+	3.997)
=	-12.408

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.434)	-	(11.713	+	0	+	6.341)
=	-15.62

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Humacyte's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-144.371	/	544.824
	=	-26.50 %

Humacyte EBIT Related Terms

Thank you for viewing the detailed overview of Humacyte's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Humacyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2525 East North Carolina Highway 54, Durham, NC, USA, 27713

Website

https://www.humacyte.com

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Executives

Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Laura E Niklason	director, 10 percent owner, officer: President, CEO and Director	35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan	director, 10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Kathleen Sebelius	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Dale A. Sander	officer: CFO & CCDO	11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
Heather Ledbetter Prichard	officer: Chief Operating Officer	820 BROWNWICH STREET, WAKE FOREST NC 27587
Max N. Wallace	director	210 WEST TRYON STREET, HILLSBOROUGH NC 27278
Gordon M Binder	director	225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Ayabudge Llc	10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
William John Scheessele	officer: Chief Commercial Officer	620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao	officer: Chief Regulatory Officer	12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green	director	3185 SCENIC DRIVE, NAPA CA 94558
Diane Seimetz	director	JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh	officer: Chief Medical Officer	1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla	director	EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411